Sectors

EMA
Emera Incorporated
49.28
500 x 49.27
1000 x 49.30
bid
ask
-
0.10
0.20%
750 @ 05:26 PM
49.28 +0.00 (0.00%)
Ytd0.08%
1y7.53%
48.66
day range
49.32
45.83
52 week range
55.11
Open48.96Prev Close49.38Low48.66High49.32Mkt Cap15.14B
Vol381.48KAvg Vol456.02KEPS2.26P/E21.81Forward P/E18.86
Beta0.43Short Ratio10.02Inst. Own56.98%Dividend2.11Div Yield4.28
Ex Div Date07-31Earning11-0650-d Avg51.80200-d Avg51.291yr Est62.50

EMA News

Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
gurufocus.com
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data a

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger R

Engineers Gate Manager LP Purchases 17,165 Shares of eMagin Corporation $EMA
defenseworld.net
Engineers Gate Manager LP Purchases 17,165 Shares of eMagin Corporation $EMA

Engineers Gate Manager LP lifted its position in shares of eMagin Corporation (NYSE: EMA) by 182.6%

Extreme Delivers Industry's First Proactive, Context-Aware AI Agent for Networking
gurufocus.com
Extreme Delivers Industry's First Proactive, Context-Aware AI Agent for Networking

[url="]Extreme Networks[/url], Inc. (NASDAQ: EXTR) today announced the general availability of [url=

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia
gurufocus.com
Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Austra

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Austra

Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
gurufocus.com
Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by

Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the

Bernhard Capital Partners Completes Acquisition of New Mexico Gas Company
prnewswire.com
Bernhard Capital Partners Completes Acquisition of New Mexico Gas Company

BATON ROUGE, La., Aug. 12, 2026 /PRNewswire/ -- Bernhard Capital Partners ("Bernhard"), an infrastru

Emera Completes Sale of New Mexico Gas Company
businesswire.com
Emera Completes Sale of New Mexico Gas Company

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Inc. (TSX/NYSE: EMA) today announced the transaction to

benzinga.com
Barclays Maintains Equal-Weight on Emera, Lowers Price Target to $53

Barclays analyst Michael Lonegan maintains Emera (NYSE:EMA) with a Equal-Weight and lowers the pr

Emera Q2 Earnings Call Highlights
marketbeat.com
Emera Q2 Earnings Call Highlights

Emera TSE: EMA reported second-quarter adjusted earnings of C$212 million, or C$0.69 per share, as t

benzinga.com
Emera Q2 Adj. EPS $0.50 Misses $0.56 Estimate, Sales $1.453B

Emera (NYSE:EMA) reported quarterly earnings of $0.50 per share which missed the analyst consensus e

benzinga.com
Emera Q2 Adj. EPS $0.50 Misses $0.56 Estimate

Emera (NYSE:EMA) reported quarterly earnings of $0.50 per share which missed the analyst consensus e

Emera Reports 2026 Second Quarter Financial Results
businesswire.com
Emera Reports 2026 Second Quarter Financial Results

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Inc. (“Emera”) (TSX/NYSE: EMA) reported 2026 second qua

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
gurufocus.com
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

[url="]PepGen Inc.[/url] (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next g

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights
gurufocus.com
Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
gurufocus.com
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB R

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of

U.S. FDA Grants Orphan Drug Designation to Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
gurufocus.com
U.S. FDA Grants Orphan Drug Designation to Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FD

Final Approval Received for Emera's Sale of New Mexico Gas Company
businesswire.com
Final Approval Received for Emera's Sale of New Mexico Gas Company

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Inc. (TSX/NYSE: EMA) today announced it has received fi

Neuronata-R retains conditional approval in South Korea
gurufocus.com
Neuronata-R retains conditional approval in South Korea

Neuronata-R retains conditional approval in South Korea PR Newswire SEOUL, South Korea, July 19, 202

CORRECTING and REPLACING Emera Declares Quarterly Dividends
businesswire.com
CORRECTING and REPLACING Emera Declares Quarterly Dividends

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Series J First Preferred Share quarterly dividend in release

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia
gurufocus.com
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European

[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide aden

Emera Declares Quarterly Dividends
businesswire.com
Emera Declares Quarterly Dividends

HALIFAX, Nova Scotia--(BUSINESS WIRE)--On July 13, 2026, the Board of Directors of Emera Inc. (TSX/N

Emera Teleconference on August 7 to Discuss Q2 2026 Results
businesswire.com
Emera Teleconference on August 7 to Discuss Q2 2026 Results

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Today Emera (TSX/NYSE: EMA) announced that it will release it

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
gurufocus.com
Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN

Johnson and Johnson presents new IMAAVYÂ (nipocalimab-aahu) data at European Academy of Neurology (E

This Rambus Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday
benzinga.com
This Rambus Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday

Wall Street analysts changed outlook on top names. Check analyst ratings page for full view. See wha

This Micron Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
benzinga.com
This Micron Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed outlooks on top stocks. Check out our analyst ratings page for upgr

Earnings Scheduled For February 23, 2026
benzinga.com
Earnings Scheduled For February 23, 2026

Earnings Scheduled For November 7, 2025
benzinga.com
Earnings Scheduled For November 7, 2025

benzinga.com
Earnings Scheduled For August 8, 2025